* Line results from Phase 2 DUET study of sparsentan in
patients with focal segmental glomerulosclerosis
The post BRIEF-Retrophin announces results from phase 2 duet study of sparsentan appeared first on NASDAQ.
Forex – financial instrument.Forex news
* Line results from Phase 2 DUET study of sparsentan in
patients with focal segmental glomerulosclerosis
The post BRIEF-Retrophin announces results from phase 2 duet study of sparsentan appeared first on NASDAQ.